Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lonza GroupXSWX:LONN +2.61%83 Debt-to-EBITDA is 2.61 as of Jun. 2026, which is 1% above its 10-year median of 2.59. GuruFocus rates XSWX:LONN with a GF Score™ of 83/100 and a GF Value™ of CHF578.88 (Fairly Valued). The stock has 4 warning signs investors should review. Among 114 Medical Diagnostics & Research companies, Lonza Group ranks worse than 54.39% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Lonza Group's Debt-to-EBITDA or its related term are showing as below:
XSWX:LONN'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.23 Med: 2.59 Max: 4.16
Current: 2.75
During the past 13 years, the highest Debt-to-EBITDA Ratio of Lonza Group was 4.16. The lowest was 1.23. And the median was 2.59.
XSWX:LONN's Debt-to-EBITDA is ranked worse than 54.39% of 114
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.32
vs XSWX:LONN: 2.75
Lonza Group (XSWX:LONN) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Lonza Group Debt-to-EBITDA Related Terms
Lonza Group Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Lonza Group's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:LONN vs TMO, DHR, IDXX: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Lonza Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lonza Group Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Lonza Group's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Lonza Group's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.
Lonza Group (XSWX:LONN) has a Debt-to-EBITDA of 2.61 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Lonza Group. This is near median its historical median of 2.59. Over the past decade, Lonza Group's Debt-to-EBITDA has ranged from 1.23 to 4.16. According to the industry distribution chart, Lonza Group ranks #62 out of 114 companies in the Medical Diagnostics & Research industry, placing it in the top 54.4%.
Is Lonza Group's Debt-to-EBITDA too high?
Lonza Group's current Debt-to-EBITDA of 2.61 is near median its 10-year median of 2.59. Over the past 10 years, this metric has ranged from a low of 1.23 to a high of 4.16. The Medical Diagnostics & Research industry median Debt-to-EBITDA is 2.32. Lonza Group's value of 2.61 is 12.5% above this industry median. Based on the distribution chart, Lonza Group ranks #62 out of 114 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Lonza Group has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Lonza Group's Debt-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Lonza Group ranks #62 out of 114 companies for Debt-to-EBITDA. This places Lonza Group in the lower half of its industry. The industry median Debt-to-EBITDA is 2.32. Lonza Group's value of 2.61 is 12.5% above this benchmark. Historically, Lonza Group's own Debt-to-EBITDA has ranged from 1.23 to 4.16 over the past decade. While the company's 10-year median is 2.59 vs. the industry median of 2.32, Lonza Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.32, based on 114 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lonza Group's current Debt-to-EBITDA of 2.61 is 12.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Lonza Group. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lonza Group's current Debt-to-EBITDA is 2.61, which is near median its own 10-year median of 2.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lonza Group stock overvalued right now?
Based on GuruFocus' analysis, Lonza Group (XSWX:LONN) is currently considered Fairly Valued. The stock's GF Value™ is CHF578.88, compared to a current price of CHF574.80 — trading 0.7% below its estimated fair value. The current Debt-to-EBITDA is 2.61, which is near median its 10-year median of 2.59 and 12.5% above the Medical Diagnostics & Research industry median of 2.32. Lonza Group's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Lonza Group (XSWX:LONN), the current Debt-to-EBITDA is 2.61 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lonza Group (XSWX:LONN) Overvalued in 2026?
Based on GuruFocus' analysis, Lonza Group stock appears to be undervalued.
The current stock price of CHF574.80 is trading 0.7% below its estimated GF Value™ of CHF578.88.
GuruFocus considers Lonza Group to be Fairly Valued.
Key valuation signals for XSWX:LONN:
Debt-to-EBITDA: 2.61 (near median its 10-year median of 2.59)
GF Value™: CHF578.88 vs. price of CHF574.80 (0.7% below fair value)
Industry Position: 12.5% above the Medical Diagnostics & Research median (#62 of 114)
No single metric tells the full story. See the XSWX:LONN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lonza Group is a contract development and manufacturing organization. It operates under four segments: small molecules, biologics, cell and gene, and capsules and health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides development and manufacturing services throughout the entire lifecycle of a product, from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
83GF Score
Get the complete analysis for XSWX:LONN
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:LONN has been successfully added to your 
